{"id":6957,"date":"2025-07-22T17:34:49","date_gmt":"2025-07-22T15:34:49","guid":{"rendered":"https:\/\/value-dossier.com\/about-us\/"},"modified":"2026-03-30T15:42:00","modified_gmt":"2026-03-30T13:42:00","slug":"about-us","status":"publish","type":"page","link":"https:\/\/value-dossier.com\/en\/about-us\/","title":{"rendered":"About Us"},"content":{"rendered":"\n<section class=\"wrap_outer intro-alternative no-spacing\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"intro__text\">\n            <div class=\"okd-text\">\n                                    <div class=\"badge\">ABOUT US<\/div>\n                                <h1>WS Value &amp; Dossier GmbH<\/h1>\n                                            <\/div>\n        <\/div>\n\n    <\/div>\n    <div class=\"intro__visual\">\n        <div class=\"wrap_inner\">\n\n            <img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/team-tile-e1776148646911.jpg\" class=\"attachment-full size-full\" alt=\"\" \/>\n        <\/div>\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer textblock\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"okd-text\">\n            <h2>We Advise Innovative Pharmaceutical and Biotechnology Companies in the AMNOG Process.<\/h2>\n<p>We offer our clients highly specialized, company-specific solutions that ensure optimal economic success. Together, we develop the best strategies for optimal market access and reimbursement of their products. We offer comprehensive services covering all phases of product development up to reimbursement in the market.  <\/p>\n        <\/div>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer team\">\n    <div class=\"wrap_inner\">\n\n                    <div class=\"okd-text\">\n                <h2>Your Value &amp; Dossier Team<\/h2>\n<p>We are here for you.<\/p>\n            <\/div>\n        \n        \n            <div class=\"team-wrapper\">\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ws-n2.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ws-n2.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ws-n2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ws-n2-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Dr. Willi Schnorpfeil<\/h3>\n                            <p>Managing Partner<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                            <ul>\n                                                                            <li>\n                                                                                            <a href=\"mailto:schnorpfeil@value-dossier.com\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"tel:+49%206173%203941016\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"https:\/\/www.linkedin.com\/in\/dr-willi-schnorpfeil-21ab5a60\" target=\"_blank\" rel=\"nofollow noopener\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"https:\/\/www.xing.com\/profile\/Willi_Schnorpfeil\/cv\" target=\"_blank\" rel=\"nofollow noopener\"><\/a>\n                                                                                    <\/li>\n                                                                    <\/ul>\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Dr. Willi Schnorpfeil holds a doctorate in economics and began his career at the AOK Bundesverband. Further positions in his professional life included AOK Hessen, Merck, Novo Nordisk and working as an independent management consultant.\r\nDr. Schnorpfeil has more than 20 years of professional experience in the healthcare sector and has been advising companies strategically and operationally on all phases of early benefit assessment according to AMNOG since 2011. As project manager of numerous AMNOG dossier projects in various indications, he has extensive experience in project management and the preparation of benefit dossiers. Dr. Schnorpfeil also has special expertise in the pricing of medicinal products and supports companies as a trainer in the negotiations on the reimbursement amount.   <\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-al-n.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-al-n.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-al-n-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-al-n-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Dr. Angela Lammert<\/h3>\n                            <p>Director HTA &amp; Value Strategy<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                            <ul>\n                                                                            <li>\n                                                                                            <a href=\"mailto:lammert@value-dossier.com\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"tel:+49%206173%203941019\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                    <\/ul>\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Dr. Angela Lammert is employed as Director HTA &amp; Value Strategy at Value &amp; Dossier. She advises pharmaceutical companies in the area of market access for (innovative) medicinal products and medical devices. As a project manager in the area of AMNOG benefit dossiers, she has already gained extensive experience through numerous projects in various indications such as oncology, neurology and ophthalmology. As Director, she is your direct contact for project management, the preparation of the benefit dossier and strategic advice throughout the entire project.   <\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-sk-n2.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-sk-n2.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-sk-n2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-sk-n2-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Dr. Sandra Kiehlmeier<\/h3>\n                            <p>Director Market Access DE \/ EU<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                            <ul>\n                                                                            <li>\n                                                                                            <a href=\"mailto:kiehlmeier@value-dossier.com\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"tel:+49%206173%203941724\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                    <\/ul>\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Dr. Sandra Kiehlmeier is a biologist with a doctorate and research experience in the field of molecular tumor biology. She has been part of the WS Value &amp; Dossier team since 2021 and has supervised several projects in various indication areas, such as nephrology and neurology. Her responsibilities as Director Market Access DE \/ EU include strategy development for market access of new medicinal products, project management of reimbursement projects, the writing of AMNOG benefit dossiers, and the calculation of price analyses. She is also your contact person for all questions relating to the EU-HTA process.   <\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jg-n2.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jg-n2.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jg-n2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jg-n2-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Julia Gerbeth, M. Sc.<\/h3>\n                            <p>Medical Writer \/ Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                            <ul>\n                                                                            <li>\n                                                                                            <a href=\"mailto:gerbeth@value-dossier.com\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"tel:+49%206173%203941020\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                    <\/ul>\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Julia Gerbeth is a medical biologist and worked for four years at the Paul-Ehrlich-Institut (PEI), the Federal Institute for Vaccines and Biomedical Medicinal Products. Here she worked in various departments within the Virology department and gained experience in licensing-based research, basic research and batch testing of vaccines. She also contributed to several scientific publications there. As a Medical Writer and Market Access Manager, she supports the Value &amp; Dossier team, using her experience primarily in the preparation of benefit dossiers.   <\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-mw-n.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-mw-n.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-mw-n-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-mw-n-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Michelle Woods, M.Sc.<\/h3>\n                            <p>Senior Medical Writer\/ Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                            <ul>\n                                                                            <li>\n                                                                                            <a href=\"mailto:henkel@value-dossier.com\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                            <li>\n                                                                                            <a href=\"tel:+49%206173%203941020\" target=\"_self\"><\/a>\n                                                                                    <\/li>\n                                                                    <\/ul>\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Michelle Woods is a biologist and has researched cancer genetics for over six years at the Institute of Genetics at the Justus Liebig University Giessen. The research focus was on the epigenetic regulation of tumor suppressor genes and the resulting influence on cell cycle-relevant signaling pathways. Her responsibilities as Senior Medical Writer \/ Market Access Manager include the preparation of benefit dossiers and strategic advice on the AMNOG process. As a native English speaker, she supports the Value &amp; Dossier team with publications and international projects.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-cb-n.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-cb-n.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-cb-n-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-cb-n-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Dr. Christopher Bell<\/h3>\n                            <p>Medical Writer \/ Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Christopher Bell is a neurobiologist and has researched presynaptic calcium channels for 5 years at the Institute of Developmental Biology and Neurobiology at the Johannes Gutenberg University Mainz. His focus here was on the function of alternative splicing of voltage-gated calcium channels in relation to synaptic transmission. As a Medical Writer and Market Access Manager, Christopher is responsible for the preparation of benefit dossiers as part of the AMNOG process at Value &amp; Dossier.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-anl-n.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-anl-n.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-anl-n-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-anl-n-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Anna Lenhart, M.Sc.<\/h3>\n                            <p>Medical Writer \/ Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Anna Lenhart is a biologist and conducted research at the Institute for Molecular and Organismic Evolutionary Biology at the Johannes Gutenberg University in Mainz. Her scientific focus was in molecular biology, with a particular focus on gene expression analyses. As a Medical Writer and Market Access Manager at Value &amp; Dossier, she is responsible for the preparation of benefit dossiers as part of the AMNOG process and specifically incorporates her scientific expertise and her experience in medical writing into interdisciplinary projects.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ek-n2.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ek-n2.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ek-n2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-ek-n2-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Emilia K\u00f6rner, M. Sc.<\/h3>\n                            <p>Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Emilia K\u00f6rner studied biology at TU Darmstadt and at the Johannes Gutenberg University Mainz. Her focus was on molecular microbiology and genetics as well as bioinformatics and data science. As Market Access Manager, she is responsible for projects in the area of market access, reimbursement and communication of medicinal products and medical devices at WS Value &amp; Dossier.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"385\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jb-n2.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jb-n2.jpg 996w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jb-n2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-jb-n2-768x432.jpg 768w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Jessika Buchwaldt, M. Sc.<\/h3>\n                            <p>Medical Writer \/ Market Access Manager<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Jessika Buchwaldt has a master&#8217;s degree in biology and has worked in the Department of Pathology at the University Medical Center Mainz in recent years, where she focused on molecular pathological issues. In her research, she analyzed cellular signaling pathways in tumors, in particular with regard to their importance for targeted therapies and personalized oncology. As a Medical Writer and Market Access Manager at Value &amp; Dossier, she is responsible for the preparation of benefit dossiers as part of the AMNOG process and specifically incorporates her scientific expertise and her experience in medical writing into interdisciplinary projects.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"456\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf.jpg 1600w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-sf-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Sandra Fraatz<\/h3>\n                            <p>Assistant to the Management<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Sandra Fraatz is a trained office administrator and has more than 20 years of professional experience in the field of finance and contract management. She has been working at Value &amp; Dossier since 2023.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"team-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"684\" height=\"456\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs.jpg\" class=\"attachment-684 size-684\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs.jpg 1600w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/09\/vd-cs-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 684px) 100vw, 684px\" \/>                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3>Christian Schneider<\/h3>\n                            <p>Student Assistant<\/p>\n                        <\/div>\n                        <div class=\"team-contact\">\n                                                    <\/div>\n                        <div class=\"okd-text read-more\">\n                            <p>Christian Schneider is studying industrial engineering with a focus on electrical engineering and information technology at TU Darmstadt. He works at Value &amp; Dossier as a student assistant.<\/p>\n                            <a href=\"#more\">Read more<\/a>\n                        <\/div>\n                    <\/article>\n\n                \n            <\/div>\n\n            <script>\n                jQuery(function($) {\n\n                    $('.read-more').each(function() {\n\n                        let textBlock = $(this).find('p'),\n                            moreLink = $(this).find('a[href=\"#more\"]');\n\n                        if( textBlock[0].scrollHeight <= textBlock.outerHeight() ) {\n                            textBlock.addClass('no-truncate');\n                            moreLink.remove();\n                        }\n\n                        moreLink.click(function(e) {\n                            e.preventDefault();\n\n                            textBlock.toggleClass('show');\n                            $(this).toggleClass('active');\n\n                            if($(this).text() == 'Mehr lesen') {\n                                $(this).text('Read less');\n                            } else {\n                                $(this).text('Read more');\n                            }\n                        });\n\n\n                    });\n\n                });\n            <\/script>\n\n        \n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer textblock\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"okd-text\">\n            <h2>Our Guiding Principle<\/h2>\n<h3>Vision and Mission<\/h3>\n<p>We offer our clients highly specialized, company-specific solutions that ensure optimal economic success. Together, we develop the best strategies for optimal market access and reimbursement of their products. We offer comprehensive services covering all phases of product development up to reimbursement in the market.  <\/p>\n<h3>These Include:<\/h3>\n<ul>\n<li>study planning with regard to approval and reimbursement<\/li>\n<li>market research and price analysis to develop an optimal market price<\/li>\n<li>the preparation of dossiers to represent the value of the products appropriately within the framework of benefit assessment procedures<\/li>\n<li>support in consultations and price negotiations with reimbursement institutions in order to achieve a maximum economic result<\/li>\n<li>support with formal reimbursement requirements (market access tools) in order to process applications and procedures for reimbursement in a timely manner.<\/li>\n<\/ul>\n        <\/div>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer textblock\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"okd-text\">\n                    <\/div>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer brands\">\n    <div class=\"wrap_inner\">\n\n                    <div class=\"okd-text\">\n                <h2>Our Network<\/h2>\n<p>Association memberships and cooperation partners<\/p>\n            <\/div>\n        \n        \n            <div class=\"brands-wrapper\">\n\n                \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.eucope.org\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/eucope-logo.svg\" class=\"attachment-full size-full\" alt=\"\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/dfgma.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"2217\" height=\"950\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo.png 2217w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo-300x129.png 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo-1024x439.png 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo-768x329.png 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo-1536x658.png 1536w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dfgma-logo-2048x878.png 2048w\" sizes=\"auto, (max-width: 2217px) 100vw, 2217px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.ebm-netzwerk.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/ebm-netzwerk-logo.svg\" class=\"attachment-full size-full\" alt=\"\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.dggoe.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"304\" height=\"143\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dggoe-logo.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dggoe-logo.png 304w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/dggoe-logo-300x141.png 300w\" sizes=\"auto, (max-width: 304px) 100vw, 304px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.bpi.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/bpi-logo.svg\" class=\"attachment-full size-full\" alt=\"\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.pharmaqm.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1286\" height=\"316\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/pharmaqm-logo.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/pharmaqm-logo.png 1286w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/pharmaqm-logo-300x74.png 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/pharmaqm-logo-1024x252.png 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/pharmaqm-logo-768x189.png 768w\" sizes=\"auto, (max-width: 1286px) 100vw, 1286px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/vitis-healthcare.com\/\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"259\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/vitis-healthcare-logo.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/vitis-healthcare-logo.png 1000w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/vitis-healthcare-logo-300x78.png 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/vitis-healthcare-logo-768x199.png 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.forum-institut.de\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/foruminstitut-logo.svg\" class=\"attachment-full size-full\" alt=\"\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"http:\/\/statistik-beratung.net\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"351\" height=\"75\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/mhstatistik-logo.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/mhstatistik-logo.png 351w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/mhstatistik-logo-300x64.png 300w\" sizes=\"auto, (max-width: 351px) 100vw, 351px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                                    <a href=\"https:\/\/www.afs-braeuer.de\/\" target=\"_blank\" rel=\"noopener nofollow\"><\/a>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"388\" height=\"208\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/Arbeitsgemeinschaft-fuer-Sozialforschung-e1772799205450.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/Arbeitsgemeinschaft-fuer-Sozialforschung-e1772799205450.png 388w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/Arbeitsgemeinschaft-fuer-Sozialforschung-e1772799205450-300x161.png 300w\" sizes=\"auto, (max-width: 388px) 100vw, 388px\" \/>                    <\/div>\n\n                    \n                    <div class=\"brand\">\n                                            <\/div>\n\n                    \n                    <div class=\"brand\">\n                                            <\/div>\n\n                    \n            <\/div>\n\n        \n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6957","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=6957"}],"version-history":[{"count":12,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6957\/revisions"}],"predecessor-version":[{"id":7808,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6957\/revisions\/7808"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=6957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}